Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
TNFRSF11B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 11B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TNFRSF11B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 11B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF11B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GPR31 Biologics Sequence Review Report 2026: 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GPR31 Biologics Sequence Review Report 2026: 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic acid receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR31 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TNFRSF10A Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 10A Similarity and Patent-Risk Signals
8 min read
TNFRSF10A Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 10A Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF10A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TLR2 Biologics Sequence Review Report 2026: Toll-like receptor 2 Similarity and Patent-Risk Signals
8 min read
TLR2 Biologics Sequence Review Report 2026: Toll-like receptor 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TLR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TLR5 Biologics Sequence Review Report 2026: Toll-like receptor 5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TLR5 Biologics Sequence Review Report 2026: Toll-like receptor 5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TLR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB1BP1 Biologics Sequence Review Report 2026: Integrin beta-1-binding protein 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITGB1BP1 Biologics Sequence Review Report 2026: Integrin beta-1-binding protein 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB1BP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL13 Biologics Sequence Review Report 2026: C-X-C motif chemokine 13 Similarity and Patent-Risk Signals
8 min read
CXCL13 Biologics Sequence Review Report 2026: C-X-C motif chemokine 13 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCL13 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF17 Biologics Sequence Review Report 2026: Fibroblast growth factor 17 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF17 Biologics Sequence Review Report 2026: Fibroblast growth factor 17 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
VEGFD Biologics Sequence Review Report 2026: Vascular endothelial growth factor D Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VEGFD Biologics Sequence Review Report 2026: Vascular endothelial growth factor D Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of VEGFD protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF16 Biologics Sequence Review Report 2026: Fibroblast growth factor 16 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF16 Biologics Sequence Review Report 2026: Fibroblast growth factor 16 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF10 Biologics Sequence Review Report 2026: Fibroblast growth factor 10 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF10 Biologics Sequence Review Report 2026: Fibroblast growth factor 10 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL16 Biologics Sequence Review Report 2026: C-C motif chemokine 16 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL16 Biologics Sequence Review Report 2026: C-C motif chemokine 16 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCL16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →